IS3631A7 - Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra - Google Patents

Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra

Info

Publication number
IS3631A7
IS3631A7 IS3631A IS3631A IS3631A7 IS 3631 A7 IS3631 A7 IS 3631A7 IS 3631 A IS3631 A IS 3631A IS 3631 A IS3631 A IS 3631A IS 3631 A7 IS3631 A7 IS 3631A7
Authority
IS
Iceland
Prior art keywords
interferons
production
blood cell
white blood
increased stability
Prior art date
Application number
IS3631A
Other languages
English (en)
Inventor
Ferro Alberto
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of IS3631A7 publication Critical patent/IS3631A7/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS3631A 1989-09-28 1990-09-27 Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra IS3631A7 (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
IS3631A7 true IS3631A7 (is) 1991-03-29

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3631A IS3631A7 (is) 1989-09-28 1990-09-27 Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra

Country Status (26)

Country Link
EP (1) EP0420049B1 (is)
JP (1) JPH03130232A (is)
KR (1) KR910005886A (is)
CN (1) CN1050503A (is)
AR (1) AR244551A1 (is)
AT (1) ATE92334T1 (is)
AU (1) AU636653B2 (is)
CA (1) CA2024046A1 (is)
CZ (1) CZ277712B6 (is)
DD (1) DD298054A5 (is)
DE (1) DE59002183D1 (is)
FI (1) FI904756A0 (is)
HU (1) HU205555B (is)
IE (1) IE903479A1 (is)
IL (1) IL95769A0 (is)
IS (1) IS3631A7 (is)
MC (1) MC2149A1 (is)
MX (1) MX22522A (is)
MY (1) MY106615A (is)
NO (1) NO904218L (is)
NZ (1) NZ235153A (is)
PH (1) PH27531A (is)
PT (1) PT95454A (is)
RU (1) RU2008017C1 (is)
YU (1) YU184090A (is)
ZA (1) ZA907579B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6794194A (en) * 1993-05-18 1994-12-20 Bukh Meditec A/S A method for the preparation of interferons
DK0920329T3 (da) * 1996-05-09 2003-01-27 Feronpatent Ltd Stabilisering af interferoner i vandig opløsning med gummiarabicum
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
JP3643034B2 (ja) * 1998-03-26 2005-04-27 シェーリング コーポレイション PEG−インターフェロンα結合体の保護のための処方物
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
JP4971160B2 (ja) 2004-08-12 2012-07-11 シェーリング コーポレイション 安定するpeg化インターフェロン処方物
DE102004048379A1 (de) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Federelement aus gesputterter Formgedächtnis-Legierung
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
ATE31023T1 (de) * 1983-04-28 1987-12-15 Armour Pharma Pharmazeutische zubereitung mit gehalt an gereinigtem fibrinonectin.
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
ES8705761A1 (es) * 1985-03-25 1987-05-16 Schering Corp Un metodo para preparar una formulacion liofilizada y estabilizada de gamma interferon
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
IE903479A1 (en) 1991-04-10
MC2149A1 (fr) 1992-03-10
HUT56284A (en) 1991-08-28
ZA907579B (en) 1991-06-26
CZ277712B6 (en) 1993-03-17
EP0420049A1 (de) 1991-04-03
JPH03130232A (ja) 1991-06-04
AU636653B2 (en) 1993-05-06
NO904218L (no) 1991-04-02
PT95454A (pt) 1991-05-22
RU2008017C1 (ru) 1994-02-28
NO904218D0 (no) 1990-09-27
DD298054A5 (de) 1992-02-06
FI904756A0 (fi) 1990-09-27
HU205555B (en) 1992-05-28
CS432890A3 (en) 1992-12-16
KR910005886A (ko) 1991-04-27
ATE92334T1 (de) 1993-08-15
YU184090A (sh) 1992-09-07
MX22522A (es) 1993-10-01
AU6309890A (en) 1991-04-11
NZ235153A (en) 1993-03-26
MY106615A (en) 1995-06-30
CA2024046A1 (en) 1991-03-29
HU906021D0 (en) 1991-03-28
IL95769A0 (en) 1991-06-30
DE59002183D1 (de) 1993-09-09
EP0420049B1 (de) 1993-08-04
CN1050503A (zh) 1991-04-10
AR244551A1 (es) 1993-11-30
PH27531A (en) 1993-08-18

Similar Documents

Publication Publication Date Title
DK166087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
NO910295D0 (no) Hyaluronsyre-estere og fremgangsmaate derav.
DK699688D0 (da) Polymerpartikler og fremgangsmaade til fremstilling deraf
PT87399A (pt) Foam-fiber composite and process
DK506389A (da) Fremgangsmaade og anlaeg til diagrafi i ikke eruptiv produktionsbroend
DK3687D0 (da) Polypeptider og fremgangsmaade til fremstilling deraf
DK522487A (da) Imidazopyridinforbindelse og fremgangsmaade til fremstilling deraf
NO882385D0 (no) Polypeptid og produksjon derav.
DK184587D0 (da) Tiolaktam-n-eddikesyrederivater, produktion og anvendelse deraf
ATE117937T1 (de) Herstellungsverfahren von zellkunststoff.
IS3631A7 (is) Interferons úr hvítum blóðkornum með auknum stöðugleika og aðferð til framleiðslu þeirra
DK96394A (da) 5-Halogenalkylidinimono-1-arylpyrazoler og fremgangsmåde til fremstilling deraf
DK269987D0 (da) Enzym og fremgangsmaade til fremstilling deraf
DK450688D0 (da) Konditioneringsmidler og fremstilling deraf
DK203087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
DK48986D0 (da) Vaevsdyrkning og produktion i permeable geler
DK270087D0 (da) Enzym og fremgangsmaade til fremstilling deraf
DK585988A (da) Isopolypeptider og fremgangsmaade til fremstilling deraf
DK265288D0 (da) Oximino-ether-forbindelser og fremgangsmaade til fremstilling deraf
DE3675631D1 (de) In-vitro-kulturverfahren.
DE3776429D1 (de) Regalstruktur und deren herstellungsverfahren.
TR24296A (tr) Ferrokrom ueretimine mahsus usul ve tertibat
KR890700674A (ko) 인간 인터로이킨 3생산세포 및 인간인터로이킨 3의 제조방법
DK152388D0 (da) Blegemiddelkompostion og blegeproces
DK152488D0 (da) Blegemiddelkomposition og blegeproces